Allergan Inc (AGN) 198.65 $AGN
Physicians Continue to Voice Strong Support for Allergan via Open Letters to the Eye Care Community
Business Wire - Fri Nov 14, 8:00AM CST
Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company"
today announced results from a recent survey of eye care professionals and the availability of an open letter website in response to requests from physician customers for a platform to voice their concerns regarding the unsolicited proposal from Valeant Pharmaceuticals International, Inc. ("Valeant" to acquire Allergan.
AGN: 198.65 (+2.44), VRX.TO: 151.47 (+1.32)
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST
ZTS: 43.14 (-0.10), AGN: 198.65 (+2.44), VRX: 134.21 (+2.31), ACT: 243.77 (+2.14)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.14 (-0.10), AGN: 198.65 (+2.44), ACT: 243.77 (+2.14), VRX: 134.21 (+2.31)
Allergan Has Returned 18.0% Since SmarTrend Recommendation (AGN)
Comtex SmarTrend(R) - Thu Nov 13, 11:14AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 17.97% as of today's recent price of $197.14.
AGN: 198.65 (+2.44)
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 198.65 (+2.44), VRX: 134.21 (+2.31), ACT: 243.77 (+2.14)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 198.65 (+2.44), JNJ: 108.16 (-0.91), GILD: 102.06 (-2.14), ABBV: 64.00 (+0.37)
FDA Approves New Styles of Allergan's NATRELLE(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Business Wire - Wed Nov 12, 3:50PM CST
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.
AGN: 198.65 (+2.44)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.14 (-0.10), AGN: 198.65 (+2.44), VRX: 134.21 (+2.31), ACT: 243.77 (+2.14)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 198.65 (+2.44), ACT: 243.77 (+2.14)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 198.65 (+2.44), ABBV: 64.00 (+0.37), SNY: 46.68 (+0.15), REGN: 395.20 (-7.43)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.14 (-0.10), AGN: 198.65 (+2.44), HLF: 38.50 (+0.65), VRX: 134.21 (+2.31), PFE: 30.34 (-0.08), MRK: 59.07 (-0.47), LLY: 67.33 (-0.35)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.75 (unch), AGN: 198.65 (+2.44), ACT: 243.77 (+2.14), IRWD: 13.13 (-0.36), CBST: 70.52 (-1.22), PFE: 30.34 (-0.08)
Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST
AGN: 198.65 (+2.44), VRX: 134.21 (+2.31)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 76.28 (-1.05), SJR: 26.82 (+0.41), PRGO: 154.46 (-1.07), XYL: 37.62 (+0.17), CHRW: 73.07 (-0.04), MDLZ: 38.16 (-0.07), MKC: 72.54 (-0.72), MDU: 25.09 (+0.09), SYY: 38.58 (-0.16), PDCO: 45.24 (-0.46), PNR: 68.66 (+0.19), TRI: 38.43 (+0.35), UPS: 106.83 (-0.96), PEP: 97.72 (-0.82), AGN: 198.65 (+2.44), MSI: 65.25 (+0.82), NOV: 71.34 (-0.18), NWN: 46.13 (-0.59), EGN: 67.96 (+1.00), EBAY: 54.36 (-0.01), QCOM: 70.85 (+0.20), AMAT: 22.82 (+0.20), ACN: 84.64 (+0.20), AAPL: 114.18 (+1.36), MA: 84.05 (-0.15), SCHW: 28.87 (+0.08), STR: 23.37 (-0.39), SE: 38.12 (+0.26), GAS: 51.45 (-0.20), IRM: 37.69 (-0.68), WM: 49.09 (-0.28), CMP: 88.83 (+0.46), VRSK: 62.87 (-0.29), GILD: 102.06 (-2.14), EXPD: 43.92 (+0.02), TFX: 114.83 (+0.19), CVS: 89.13 (-1.00), PG: 88.11 (-0.49), PX: 125.86 (-0.87), NVS: 93.95 (-0.43)
Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws
Business Wire - Wed Nov 12, 6:01AM CST
--Amendments Follow Meetings with Major Stockholders to Solicit Their Perspectives
AGN: 198.65 (+2.44)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 198.65 (+2.44), GILD: 102.06 (-2.14), ABBV: 64.00 (+0.37), BMY: 57.95 (+0.15)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 198.65 (+2.44), VRX: 134.21 (+2.31), ACT: 243.77 (+2.14)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 106.90 (-0.31), AGN: 198.65 (+2.44), JNJ: 108.16 (-0.91), DNDN: 0.11 (-0.02)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 198.65 (+2.44), ZTS: 43.14 (-0.10), ACT: 243.77 (+2.14), VRX: 134.21 (+2.31)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.75 (unch), AGN: 198.65 (+2.44), ACT: 243.77 (+2.14), VRX: 134.21 (+2.31), MDT: 68.95 (-0.43), SLXP: 102.32 (+5.33), SNY: 46.68 (+0.15)
Physicians Continue to Voice Strong Support for Allergan via Open Letters to the Eye Care Community
Business Wire - Fri Nov 14, 8:00AM CST
Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company"
today announced results from a recent survey of eye care professionals and the availability of an open letter website in response to requests from physician customers for a platform to voice their concerns regarding the unsolicited proposal from Valeant Pharmaceuticals International, Inc. ("Valeant" to acquire Allergan. AGN: 198.65 (+2.44), VRX.TO: 151.47 (+1.32)
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST
ZTS: 43.14 (-0.10), AGN: 198.65 (+2.44), VRX: 134.21 (+2.31), ACT: 243.77 (+2.14)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.14 (-0.10), AGN: 198.65 (+2.44), ACT: 243.77 (+2.14), VRX: 134.21 (+2.31)
Allergan Has Returned 18.0% Since SmarTrend Recommendation (AGN)
Comtex SmarTrend(R) - Thu Nov 13, 11:14AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 17.97% as of today's recent price of $197.14.
AGN: 198.65 (+2.44)
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 198.65 (+2.44), VRX: 134.21 (+2.31), ACT: 243.77 (+2.14)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 198.65 (+2.44), JNJ: 108.16 (-0.91), GILD: 102.06 (-2.14), ABBV: 64.00 (+0.37)
FDA Approves New Styles of Allergan's NATRELLE(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Business Wire - Wed Nov 12, 3:50PM CST
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.
AGN: 198.65 (+2.44)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.14 (-0.10), AGN: 198.65 (+2.44), VRX: 134.21 (+2.31), ACT: 243.77 (+2.14)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 198.65 (+2.44), ACT: 243.77 (+2.14)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 198.65 (+2.44), ABBV: 64.00 (+0.37), SNY: 46.68 (+0.15), REGN: 395.20 (-7.43)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.14 (-0.10), AGN: 198.65 (+2.44), HLF: 38.50 (+0.65), VRX: 134.21 (+2.31), PFE: 30.34 (-0.08), MRK: 59.07 (-0.47), LLY: 67.33 (-0.35)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.75 (unch), AGN: 198.65 (+2.44), ACT: 243.77 (+2.14), IRWD: 13.13 (-0.36), CBST: 70.52 (-1.22), PFE: 30.34 (-0.08)
Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST
AGN: 198.65 (+2.44), VRX: 134.21 (+2.31)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 76.28 (-1.05), SJR: 26.82 (+0.41), PRGO: 154.46 (-1.07), XYL: 37.62 (+0.17), CHRW: 73.07 (-0.04), MDLZ: 38.16 (-0.07), MKC: 72.54 (-0.72), MDU: 25.09 (+0.09), SYY: 38.58 (-0.16), PDCO: 45.24 (-0.46), PNR: 68.66 (+0.19), TRI: 38.43 (+0.35), UPS: 106.83 (-0.96), PEP: 97.72 (-0.82), AGN: 198.65 (+2.44), MSI: 65.25 (+0.82), NOV: 71.34 (-0.18), NWN: 46.13 (-0.59), EGN: 67.96 (+1.00), EBAY: 54.36 (-0.01), QCOM: 70.85 (+0.20), AMAT: 22.82 (+0.20), ACN: 84.64 (+0.20), AAPL: 114.18 (+1.36), MA: 84.05 (-0.15), SCHW: 28.87 (+0.08), STR: 23.37 (-0.39), SE: 38.12 (+0.26), GAS: 51.45 (-0.20), IRM: 37.69 (-0.68), WM: 49.09 (-0.28), CMP: 88.83 (+0.46), VRSK: 62.87 (-0.29), GILD: 102.06 (-2.14), EXPD: 43.92 (+0.02), TFX: 114.83 (+0.19), CVS: 89.13 (-1.00), PG: 88.11 (-0.49), PX: 125.86 (-0.87), NVS: 93.95 (-0.43)
Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws
Business Wire - Wed Nov 12, 6:01AM CST
--Amendments Follow Meetings with Major Stockholders to Solicit Their Perspectives
AGN: 198.65 (+2.44)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 198.65 (+2.44), GILD: 102.06 (-2.14), ABBV: 64.00 (+0.37), BMY: 57.95 (+0.15)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 198.65 (+2.44), VRX: 134.21 (+2.31), ACT: 243.77 (+2.14)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 106.90 (-0.31), AGN: 198.65 (+2.44), JNJ: 108.16 (-0.91), DNDN: 0.11 (-0.02)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 198.65 (+2.44), ZTS: 43.14 (-0.10), ACT: 243.77 (+2.14), VRX: 134.21 (+2.31)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.75 (unch), AGN: 198.65 (+2.44), ACT: 243.77 (+2.14), VRX: 134.21 (+2.31), MDT: 68.95 (-0.43), SLXP: 102.32 (+5.33), SNY: 46.68 (+0.15)
